Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495924 | 0.86 | GPR142 (0.52) | GPR142PPIDBCHEMMP8L3MBTL1 | |
| SCHEMBL5495922 | 0.86 | GPR142 (0.52) | GPR142PPIDBCHEMMP8L3MBTL1 | |
| SCHEMBL17287421 | 0.79 | PPID (0.54) | GPR142PPIDMMP8POLBLTA4H | |
| SCHEMBL10073607 | 0.79 | PPID (0.54) | GPR142PPIDMMP8L3MBTL1POLB | |
| SCHEMBL14567248 | 0.79 | BCHE (0.45) | GPR142BCHEL3MBTL1TSHR | |
| SCHEMBL2896037 | 0.78 | MEN1 (0.57) | GPR142PPIDMMP8L3MBTL1POLB | |
| SCHEMBL2896038 | 0.78 | MEN1 (0.57) | GPR142PPIDMMP8L3MBTL1POLB | |
| SCHEMBL10953107 | 0.76 | GPR142 (0.52) | GPR142PPIDMMP8L3MBTL1POLB | |
| SCHEMBL5497740 | 0.76 | GPR142 (0.45) | GPR142PPIDMMP8POLBLTA4H | |
| SCHEMBL352624 | 0.75 | MMP8 (0.47) | BCHEMMP8POLBSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189708-B2 | Topical composition for skin | KAO CORPORATION (JP) | 2007-03-13 | — | — | US | disclosed |
| EP-1090625-B1 | Topical composition for the skin and use thereof | KAO CORP (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030087833-A1 | Topical composition for skin | KAO CORPORATION (JP) | 2003-05-08 | — | — | US | disclosed |
| US-6489291-B1 | Topical composition for skin | KAO CORPORATION (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1090625-A2 | Topical composition for the skin and use thereof | Kao Corporation (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087833-A1 | Topical composition for skin | CUTA, SLC38A7, CCR8 | GPR142 1372/4885PPID 3265/4885BCHE 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.